Pfizer Inc. (NYSE:PFE) Position Increased by Abner Herrman & Brock LLC

Abner Herrman & Brock LLC lifted its position in Pfizer Inc. (NYSE:PFE) by 8.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,950 shares of the biopharmaceutical company’s stock after acquiring an additional 1,136 shares during the period. Abner Herrman & Brock LLC’s holdings in Pfizer were worth $387,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in PFE. Great Waters Wealth Management raised its position in Pfizer by 3.3% during the first quarter. Great Waters Wealth Management now owns 26,969 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 868 shares during the period. Rowlandmiller & PARTNERS.ADV boosted its holdings in shares of Pfizer by 14.0% during the first quarter. Rowlandmiller & PARTNERS.ADV now owns 78,868 shares of the biopharmaceutical company’s stock worth $2,189,000 after purchasing an additional 9,702 shares during the period. Bath Savings Trust Co grew its position in Pfizer by 10.1% during the first quarter. Bath Savings Trust Co now owns 45,820 shares of the biopharmaceutical company’s stock valued at $1,272,000 after purchasing an additional 4,205 shares in the last quarter. Tompkins Financial Corp lifted its position in Pfizer by 6.3% in the 1st quarter. Tompkins Financial Corp now owns 46,234 shares of the biopharmaceutical company’s stock worth $1,283,000 after buying an additional 2,749 shares in the last quarter. Finally, Atlas Brown Inc. grew its holdings in shares of Pfizer by 4.8% during the 1st quarter. Atlas Brown Inc. now owns 70,182 shares of the biopharmaceutical company’s stock valued at $1,948,000 after acquiring an additional 3,236 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Guggenheim began coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Morgan Stanley boosted their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Monday. Ten analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus price target of $35.86.

Pfizer Stock Up 0.2 %

Shares of PFE opened at $27.46 on Thursday. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $39.24. The firm has a market capitalization of $155.60 billion, a P/E ratio of -456.76, a P/E/G ratio of 1.08 and a beta of 0.70. The company has a 50-day simple moving average of $27.61 and a 200-day simple moving average of $27.73. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The company had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company’s quarterly revenue was down 19.5% on a year-over-year basis. During the same quarter last year, the company earned $1.23 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 14th. Investors of record on Friday, May 10th were paid a $0.42 dividend. The ex-dividend date was Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 6.12%. Pfizer’s payout ratio is currently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.